Glaxosmithkline Pharmaceuticals Ltd vs Jubilant Pharmova Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Glaxosmithkline Pharmaceuticals Ltd is ₹ 2362 as of 05 May 15:30 . The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 68.1 on March 2021 to 52.5 on March 2025 . This represents a CAGR of -5.07% over 5 yearsThe P/E Ratio of Jubilant Pharmova Ltd changed from 13 on March 2021 to 16.8 on March 2025 . This represents a CAGR of 5.26% over 5 years The Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 24401 crore on March 2021 to ₹ 48743 crore on March 2025 . This represents a CAGR of 14.84% over 5 yearsThe Market Cap of Jubilant Pharmova Ltd changed from ₹ 10838 crore on March 2021 to ₹ 14220 crore on March 2025 . This represents a CAGR of 5.58% over 5 years The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 1091 crore as compare to the Sep '25 revenue of ₹ 1016 crore. This represent the growth of 7.4% The revenue of Jubilant Pharmova Ltd for the Dec '25 is ₹ 2143 crore as compare to the Sep '25 revenue of ₹ 1976 crore. This represent the growth of 8.44% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 421.44 crore as compare to the Sep '25 ebitda of ₹ 371.94 crore. This represent the growth of 13.31% The ebitda of Jubilant Pharmova Ltd for the Dec '25 is ₹ 270.2 crore as compare to the Sep '25 ebitda of ₹ 345.3 crore. This represent the decline of -21.75% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 182.33 crore to ₹ 295.62 crore over 7 quarters. This represents a CAGR of 31.80% The net profit of Jubilant Pharmova Ltd changed from ₹ 481.8 crore to ₹ 55.8 crore over 7 quarters. This represents a CAGR of -70.83% The Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 142.13 % on March 2021 to 99.54 % on March 2025 . This represents a CAGR of -6.88% over 5 yearsThe Dividend Payout of Jubilant Pharmova Ltd changed from 37.14 % on March 2021 to 414.06 % on March 2025 . This represents a CAGR of 61.97% over 5 years .

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

About Jubilant Pharmova Ltd

Jubilant Pharmova Limited was initially incorporated as 'Vam Organic Chemicals Limited' on June 21, 1978.
Company name was changed to 'Jubliant Organosys Limited' in November, 2001 and was again changed to 'Jubilant Life Sciences Limited' in October, 2009 and further it attained a new name 'Jubilant Pharmova Limited' in February, 2021. Jubilant Pharmova Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.
The Company is engaged in pharmaceuticals, contract research and development services and proprietary novel drugs.
The pharmaceuticals segment, through wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of Active Pharmaceutical Ingredients (APIs), Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile Injectables and Non-Sterile Products through 6 US FDA approved manufacturing facilities in India, USA and Canada with a network of over 48 radiopharmacies in the USA.

FAQs for the comparison of Glaxosmithkline Pharmaceuticals Ltd and Jubilant Pharmova Ltd

Which company has a larger market capitalization, Glaxosmithkline Pharmaceuticals Ltd or Jubilant Pharmova Ltd?

Market cap of Glaxosmithkline Pharmaceuticals Ltd is 40,017 Cr while Market cap of Jubilant Pharmova Ltd is 14,950 Cr

What are the key factors driving the stock performance of Glaxosmithkline Pharmaceuticals Ltd and Jubilant Pharmova Ltd?

The stock performance of Glaxosmithkline Pharmaceuticals Ltd and Jubilant Pharmova Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glaxosmithkline Pharmaceuticals Ltd and Jubilant Pharmova Ltd?

As of May 5, 2026, the Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2362.25. On the other hand, Jubilant Pharmova Ltd stock price is INR ₹938.5.

How do dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Jubilant Pharmova Ltd compare?

To compare the dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Jubilant Pharmova Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.